MY01

About MY01

MY01, Inc. operates within the medical technology sector, focusing on the diagnosis of Acute Compartment Syndrome (ACS), a severe condition that can lead to muscle death or amputation if not treated promptly. The company was founded in 2015 by a team including Charles M. C. Allan, who serves as the CTO and whose background in biomedical engineering from McGill University directly informed the product's development, alongside Dr. Edward J. Harvey, a trauma surgeon, ensuring the device addresses real-world clinical needs.

The core of MY01's business is its namesake product, the MY01 device, which is designed to provide continuous and accurate monitoring of intramuscular pressure. This addresses a significant shortcoming in orthopedic care, where the standard diagnostic methods for ACS often rely on subjective patient-reported pain levels, which can be unreliable, especially in polytrauma patients. The MY01 device offers a direct, data-driven alternative, empowering surgeons with objective information to make timely and critical decisions about surgical intervention, specifically a fasciotomy.

The device itself is a sterile, single-use tool that is placed into the muscle compartment and provides real-time pressure readings transmitted to a connected mobile application. This allows for continuous monitoring without the need for repeated, painful needle insertions. MY01's business model is centered on the sale of this single-use device to hospitals and surgical centers. The company has secured FDA 510(k) clearance and a CE Mark, enabling it to commercialize its product in major markets like the United States and Europe.

MY01 targets orthopedic and trauma surgery departments within the healthcare system. By facilitating earlier and more accurate diagnosis, the company aims to improve patient outcomes by reducing the rate of missed cases and preventing unnecessary surgical procedures. This also presents a compelling value proposition for healthcare providers by potentially lowering costs associated with complications and lengthy hospital stays stemming from delayed ACS diagnosis.